{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"medRxiv"}],"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T00:45:50Z","timestamp":1794271550748,"version":"4.9.0"},"posted":{"date-parts":[[2025,9,7]]},"group-title":"HIV\/AIDS","reference-count":10,"publisher":"openRxiv","license":[{"start":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T00:00:00Z","timestamp":1757203200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/publicdomain\/zero\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2025,9,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                <jats:p>Monoclonal antibodies (mAbs) are a major class of drugs for treatment and prevention of disease. In early clinical trials, the pharmacokinetics (pK) of mAbs are usually assessed by measuring mAb concentration in serum. However, it is not a given that the mAbs will retain full functionality over time, emphasizing the need for integrated PK and functional assessments. In a re-analysis of data from the CAPRISA 012B trial, a previously published phase 1 study evaluating mAbs CAP256V2LS and VRC07-523LS in HIV-negative women, we report an unexpected disconnect between serum bNAb concentrations and HIV neutralization activity of CAP256V2LS, with implications for ongoing assessment of passive immunization trials.<\/jats:p>","DOI":"10.1101\/2025.09.04.25334949","type":"posted-content","created":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T02:40:13Z","timestamp":1757299213000},"source":"Crossref","is-referenced-by-count":2,"title":["Rapid loss of activity but not serum concentration in a passive infusion clinical trial of an HIV neutralizing antibody"],"prefix":"10.64898","author":[{"given":"Sharana","family":"Mahomed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nonhlanhla N","family":"Mkhize","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonid A.","family":"Serebryannyy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tandile","family":"Hermanus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prudence","family":"Kgagudi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haajira","family":"Kaldine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bronwen","family":"Lambson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandeep R.","family":"Narpala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manjula","family":"Basappa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mike","family":"Castro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bob C","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Carlton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason T.","family":"Sands","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason G.","family":"Gall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard A.","family":"Koup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynn","family":"Morris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quarraisha Abdool","family":"Karim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Penny L.","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salim Abdool","family":"Karim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5731-3054","authenticated-orcid":false,"given":"Nicole","family":"Doria-Rose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"54368","reference":[{"issue":"4","key":"2025091111401411000_2025.09.04.25334949v1.1","doi-asserted-by":"crossref","first-page":"e230","DOI":"10.1016\/S2352-3018(23)00003-6","article-title":"Safety and pharmacokinetics of escalating doses of neutralising monoclonal antibody CAP256V2LS administered with and without VRC07-523LS in HIV-negative women in South Africa (CAPRISA 012B): a phase 1, dose-escalation, randomised controlled trial","volume":"10","year":"2023","journal-title":"Lancet HIV"},{"key":"2025091111401411000_2025.09.04.25334949v1.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.chom.2019.08.014"},{"key":"2025091111401411000_2025.09.04.25334949v1.3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2031738"},{"key":"2025091111401411000_2025.09.04.25334949v1.4","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002493"},{"issue":"10","key":"2025091111401411000_2025.09.04.25334949v1.5","doi-asserted-by":"crossref","first-page":"e667","DOI":"10.1016\/S2352-3018(19)30181-X","article-title":"Safety and pharmacokinetics of broadly neutralising human monoclonal antibody VRC07-523LS in healthy adults: a phase 1 dose-escalation clinical trial","volume":"6","year":"2019","journal-title":"Lancet HIV"},{"issue":"7","key":"2025091111401411000_2025.09.04.25334949v1.6","doi-asserted-by":"crossref","first-page":"e175375","DOI":"10.1172\/jci.insight.175375","article-title":"Phase 1 trial evaluating safety and pharmacokinetics of HIV-1 broadly neutralizing mAbs 10E8VLS and VRC07-523LS","volume":"9","year":"2024","journal-title":"JCI insight"},{"issue":"7","key":"2025091111401411000_2025.09.04.25334949v1.7","doi-asserted-by":"crossref","first-page":"e485","DOI":"10.1016\/S2352-3018(25)00041-4","article-title":"Safety and pharmacokinetics of N6LS, a broadly neutralising monoclonal antibody for HIV: a phase 1, open-label, dose-escalation study in healthy adults","volume":"12","year":"2025","journal-title":"Lancet HIV"},{"issue":"1","key":"2025091111401411000_2025.09.04.25334949v1.8","doi-asserted-by":"crossref","first-page":"17876","DOI":"10.1038\/s41598-022-22435-2","article-title":"Engineering of HIV-1 neutralizing antibody CAP256V2LS for manufacturability and improved half life","volume":"12","year":"2022","journal-title":"Sci Rep"},{"issue":"1","key":"2025091111401411000_2025.09.04.25334949v1.9","doi-asserted-by":"crossref","first-page":"1908030","DOI":"10.1080\/21645515.2021.1908030","article-title":"Prediction of serum HIV-1 neutralization titers of VRC01 in HIV-uninfected Antibody Mediated Prevention (AMP) trial participants","volume":"18","year":"2022","journal-title":"Hum Vaccin Immunother"},{"key":"2025091111401411000_2025.09.04.25334949v1.10","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2023-076843"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1101\/2025.09.04.25334949","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T20:45:05Z","timestamp":1768509905000},"score":1,"resource":{"primary":{"URL":"http:\/\/medrxiv.org\/lookup\/doi\/10.1101\/2025.09.04.25334949"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,7]]},"references-count":10,"URL":"https:\/\/doi.org\/10.1101\/2025.09.04.25334949","relation":{},"subject":[],"published":{"date-parts":[[2025,9,7]]},"subtype":"preprint"}}